Drug Trial Radar · NCT04161495
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Nov 19, 2019
Primary completion
Feb 3, 2022
Study completion Feb 3, 2022
Sponsor
- Lead sponsor
- Bioverativ, a Sanofi companySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for the prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life outcomes. * To evaluate the efficacy of BIVV001 for perioperative management. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the pharmacokinetics (PK) of BIVV001 based on the 1-stage activated partial thromboplastin time (aPTT) and 2-stage chromogenic coagulation factor VIII (FVIII) activity assays.
Conditions
- Factor VIII Deficiency
Interventions
efanesoctocog alfa (BIVV001)Biological
Pharmaceutical form: solution for injection Route of administration: IV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Annualized Bleeding Rate (ABR) in Arm A: ProphylaxisTime frame: Baseline to Week 52
- Observed Annualized Bleeding Rate in Arm A: ProphylaxisTime frame: Baseline to Week 52
Locations
47 sites in 19 countries. Site status is shown where the registry gives one.
Investigational Site Number 920
Los Angeles, California
Investigational Site Number 921
Los Angeles, California
Investigational Site Number 911
San Diego, California
Investigational Site Number 917
Gainesville, Florida
Investigational Site Number 919
Ann Arbor, Michigan
Investigational Site Number 908
Lansing, Michigan
Investigational Site Number 906
Las Vegas, Nevada
Investigational Site Number 902
Seattle, Washington
Investigational Site Number 136
Buenos Aires, Argentina
Investigational Site Number 137
Buenos Aires, Argentina
Investigational Site Number 139
Mendoza, Argentina
Investigational Site Number 121
Perth, Australia
Investigational Site Number 122
Sydney, Australia
Investigational Site Number 161
Brussels, Belgium
Investigational Site Number 181
Campinas, Brazil
Investigational Site Number 171
Plovdiv, Bulgaria
Investigational Site Number 172
Sofia, Bulgaria
Investigational Site Number 202
Hamilton, Canada
Investigational Site Number 205
Hamilton, Canada
Investigational Site Number 281
Brest, France
Investigational Site Number 283
Lille, France
Investigational Site Number 282
Lyon, France
Investigational Site Number 284
Marseille, France
Investigational Site Number 304
Berlin, Germany
Investigational Site Number 302
Bonn, Germany
Investigational Site Number 303
Frankfurt, Germany
Investigational Site Number 321
Athens, Greece
Investigational Site Number 312
Budapest, Hungary
Investigational Site Number 314
Debrecen, Hungary
Investigational Site Number 402
Milan, Italy
Investigational Site Number 401
Vicenza, Italy
Investigational Site Number 426
Kawasaki, Japan
Investigational Site Number 423
Kitakyushu, Japan
Investigational Site Number 425
Nagoya, Japan
Investigational Site Number 422
Nara, Japan
Investigational Site Number 421
Tokyo, Japan
Investigational Site Number 424
Tokyo, Japan
Investigational Site Number 435
Durango, Mexico
Investigational Site Number 641
Utrecht, Netherlands
Investigational Site Number 603
Daegu, South Korea
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.